Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema

Timothy J Craig, Richard L Wasserman, Robyn J Levy, Againdra K Bewtra, Lynda Schneider, Flint Packer, William H Yang, Heinz-Otto Keinecke, Peter C Kiessling, Timothy J Craig, Richard L Wasserman, Robyn J Levy, Againdra K Bewtra, Lynda Schneider, Flint Packer, William H Yang, Heinz-Otto Keinecke, Peter C Kiessling

Abstract

Introduction: Hereditary angioedema (HAE) is a rare disorder characterized by C1 esterase inhibitor (C1-INH) deficiency, resulting in periodic attacks of acute edema that can be life-threatening if they occur in the laryngeal region. We assessed the efficacy of C1-INH concentrate in the emergency treatment of rarely occurring acute laryngeal HAE attacks in a prospective, open-label clinical study.

Methods: Acute laryngeal attacks were each treated with C1-INH concentrate (Berinert) at a single dose of 20 U/kg body weight. Efficacy endpoints included time to onset of symptom relief and time to complete resolution of all symptoms, each based on the patient's assessment.

Results: All 39 laryngeal attacks in 16 patients were treated successfully. The median time to onset of symptom relief was 15 min. The median time to complete resolution of all symptoms was 8.25 h. No treatment-related serious adverse events occurred, and the treatment was well tolerated. The administration of C1-INH concentrate was not associated with any viral infections.

Conclusion: C1-INH concentrate is an effective and safe emergency treatment for providing reliable and rapid relief from the potentially life-threatening symptoms of laryngeal HAE attacks.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves for time to onset of symptom relief, as determined by the patient's assessment. The curves show by-patient and by-attack analyses in both cases in the intention-to-treat population
Fig. 2
Fig. 2
Kaplan–Meier curves for time to complete resolution of all HAE symptoms, as determined by the patient's assessment. The curves show by-patient and by-attack analyses in both cases in the intention-to-treat population

References

    1. Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions. Expet Rev Clin Immunol. 2008;4:13–20. doi: 10.1586/1744666X.4.1.13.
    1. Cicardi M, Zingale LC, Zanichelli A, et al. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother. 2007;8:3173–3181. doi: 10.1517/14656566.8.18.3173.
    1. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359:1027–1036. doi: 10.1056/NEJMcp0803977.
    1. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267–274. doi: 10.1016/j.amjmed.2005.09.064.
    1. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163:1229–1235. doi: 10.1001/archinte.163.10.1229.
    1. Farkas H, Varga L, Széplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics. 2007;120:e713–e722. doi: 10.1542/peds.2006-3303.
    1. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S30–S40. doi: 10.1016/S1081-1206(10)60584-4.
    1. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51–S131. doi: 10.1016/j.jaci.2004.06.047.
    1. Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci. 1982;284:2–9. doi: 10.1097/00000441-198207000-00001.
    1. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75:349–354. doi: 10.4065/75.4.349.
    1. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. JADA. 2003;134:1088–1094.
    1. Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005;45:1774–1784. doi: 10.1111/j.1537-2995.2005.00602.x.
    1. Levi M, Choi G, Picavet C, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. 2006;117:904–908. doi: 10.1016/j.jaci.2006.01.002.
    1. Carugati A, Pappalardo E, Zingale LC, et al. C1-inhibitor deficiency and angioedema. Mol Immunol. 2001;38:161–173. doi: 10.1016/S0161-5890(01)00040-2.
    1. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1-esterase inhibitor (C1-INH) concentrate compared to placebo in patients with acute abdominal or facial HAE attacks. J Allergy Clin Immunol. 2009;124(4):801–808. doi: 10.1016/j.jaci.2009.07.017.
    1. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161:714–718. doi: 10.1001/archinte.161.5.714.
    1. Agostoni A, Aygören-Pürsün E, Binkley KE. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51–S131. doi: 10.1016/j.jaci.2004.06.047.
    1. Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, Zerlauth G, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 1998;38(6):540–549. doi: 10.1046/j.1537-2995.1998.38698326333.x.
    1. Frank MM. Hereditary angioedema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S23–S29. doi: 10.1016/S1081-1206(10)60583-2.
    1. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334(25):1630–1634. doi: 10.1056/NEJM199606203342503.
    1. Zuraw BL. Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S13–S18. doi: 10.1016/S1081-1206(10)60581-9.
    1. Farkas H, Jakab L, Temesszentandrási G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol. 2007;120(4):941–947. doi: 10.1016/j.jaci.2007.06.026.
    1. Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci. 2003;29:221–227. doi: 10.1016/S1473-0502(03)00164-2.
    1. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci. 2003;29(3):235–238. doi: 10.1016/j.transci.2003.08.007.
    1. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine. 1992;71:206–215. doi: 10.1097/00005792-199207000-00003.
    1. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency consensus document. Clin Exp Immunol. 2005;139:379–394. doi: 10.1111/j.1365-2249.2005.02726.x.
    1. Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int J Clin Pract. 2005;59:594–599. doi: 10.1111/j.1742-1241.2005.00352.x.
    1. de Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci. 2003;29(3):247–254. doi: 10.1016/j.transci.2003.08.006.
    1. Gröner A, Nowak T, Schäfer W: An integrated approach to effective pathogen reduction for a plasma-derived C1 inhibitor concentrate. Kongressausgabe 52. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung e.V. in Wiesbaden. Hämostaseologie 28(1/2) Poster Abstract 2008;P·21–02

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe